MUC5B levels in submandibular gland saliva of patients treated with radiotherapy for head-and-neck cancer: A pilot study

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Dijkema, Tim ^a   Terhaard, Chris H J ^a   Roesink, Judith M ^a   Raaijmakers, Cornelis P J ^a   van den Keijbus, Petra A M ^b   Brand, Henk S ^b   Veerman, Enno C I ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Head and neck cancer; MUC5B; Mucin; Radiotherapy; Submandibular gland; Xerostomia

Indexed keywords

MUCIN 5B;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUESTIONNAIRE; SALIVA; SUBMANDIBULAR GLAND; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCIN-5B; PILOT PROJECTS; RADIOTHERAPY; SALIVA; SUBMANDIBULAR GLAND; XEROSTOMIA;

EID: 84862216626     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-91     Document Type: Article

References (17)

1. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008, 26:3770-3776. 10.1200/JCO.2007.14.6647, 18669465.
2. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:751-760. 10.1016/j.ijrobp.2007.04.021, 17560735.
3. Braam PM, Terhaard CH, Roesink JM, Raaijmakers CP. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:975-980. 10.1016/j.ijrobp.2006.06.045, 16965864.
4. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873-4879. 10.1200/JCO.2007.11.5501, 17971582.
5. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991. 10.1016/j.ijrobp.2006.06.013, 17145528.
6. Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch CA, Eisbruch A. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys in press,
7. Alliende C, Kwon YJ, Brito M, Molina C, Aguilera S, Pérez P, Leyton L, Quest AF, Mandel U, Veerman E, Espinosa M, Clausen H, Leyton C, Romo R, González MJ. Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome. Ann Rheum Dis 2008, 67:1480-1487. 10.1136/ard.2007.078246, 17998215.
8. Eliasson L, Carlén A. An update on minor salivary gland secretions. Eur J Oral Sci 2010, 118:435-442. 10.1111/j.1600-0722.2010.00766.x, 20831576.
9. Dijkema T, Terhaard CH, Roesink JM, Braam PM, van Gils CH, Moerland MA, Raaijmakers CP. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1101-1109. 10.1016/j.ijrobp.2008.02.059, 18472355.
10. Houweling AC, Dijkema T, Roesink JM, Terhaard CH, Raaijmakers CP. Sparing the contralateral submandibular gland in oropharyngeal cancer patients: a planning study. Radiother Oncol 2008, 89:64-70. 10.1016/j.radonc.2008.04.008, 18501984.
11. Silva DG, Stevens RH, Macedo JM, Hirata R, Pinto AC, Alves LM, Veerman EC, Tinoco EM. Higher levels of salivary MUC5B and MUC7 in individuals with gastric diseases who harbor Helicobacter pylori. Arch Oral Biol 2009, 54:86-90. 10.1016/j.archoralbio.2008.08.003, 18817906.
12. Veerman ECI, Bolscher JGM, Appelmelk BJ, Bloemena E, van den Berg TK, Nieuw Amerongen AV. A monoclonal antibody directed against high M(r) salivary mucins recognizes the SO3-3Gal beta 1-3GlcNAc moiety of sulfo-Lewis(a): a histochemical survey of human and rat tissue. Glycobiology 1997, 7:37-43. 10.1093/glycob/7.1.37, 9061363.
13. Rayment SA, Liu B, Offner GD, Oppenheim FG, Troxler RF. Immunoquantification of human salivary mucins MG1 and MG2 in stimulated whole saliva: factors influencing mucin level. J Dent Res 2000, 79:1765-1772. 10.1177/00220345000790100601, 11077992.
14. Tabak LA. In defense of the oral cavity: structure, biosynthesis, and function of salivary mucins. Annu Rev Physiol 1995, 57:547-564. 10.1146/annurev.ph.57.030195.002555, 7778877.
15. Pramanik R, Osailan SM, Challacombe SJ, Urquhart D, Proctor GB. Protein and mucin retention on oral mucosal surfaces in dry mouth patients. Eur J Oral Sci 2010, 118:245-253. 10.1111/j.1600-0722.2010.00728.x, 20572857.
16. Veerman ECI, van den Keijbus PAM, Nazmi K, Vos W, van der Wal JE, Bloemena E, Bolscher JGM, Nieuw Amerongen AV. Distinct localization of MUC5B glycoforms in the human salivary glands. Glycobiology 2003, 13:363-366. 10.1093/glycob/cwg037, 12626387.
17. Nieuw Amerongen AV, Bolscher JGM, Veerman ECI. Salivary mucins: protective functions in relation to their diversity. Glycobiology 1995, 5:733-740. 10.1093/glycob/5.8.733, 8720071.